Opinion

Jim O’Neill: The Best Trump Pick You’ve Never Heard Of

Reuters

Mark Lutter Lead Economist, NeWAY Capital
Font Size:

The FDA regulates 25% of American consumer spending. And perhaps more importantly, the FDA regulates some of the most critical goods sold in our economy, such as life-saving drugs and medical devices. Delaying the approval of life-saving drugs and medical devices, and discouraging their development through those delays, costs lives.

Unfortunately, the FDA has been a major roadblock for medical innovation, through its delays and bureaucratic requirements. It costs about $2.6 billion to get a new drug approved by the FDA, according to a Tufts study. Contrast that with the largely unregulated world of computers and software, which has become synonymous with technology, where within a generation, we now have personal computers, tablets, and smartphones. What does the medical industry have to show for that same time period?

To a large extent, the lack of progress is because the government is strangling innovation. And that can soon change if Donald Trump nominates Jim O’Neill to lead the Food and Drug Commission (FDA).

O’Neill met with Trump last week to discuss becoming FDA commissioner. He’s a passionate advocate of finding new ways for the government to spur more innovation in medicine. If nominated and confirmed, he would make the FDA an ally of innovation instead of an obstacle.

O’Neill is currently managing director of Mithril Capital Management, a venture capital firm co-founded by Peter Thiel. Before working for Thiel, he spent six years working in senior roles at the Department of Health and Human Services under President George W. Bush, and worked closely with the FDA.

While Apple and Google outgrew their garages into multibillion-dollar companies, the government stood in the way of any aspiring Steve Jobses and Mark Zuckerbergs in the medical industry that wanted to get their innovations to market and improve on them. In fact, not only is over regulation suppressing health care startups, it’s also scaring off some of our best and brightest companies.  Sergei Brin, Google co-founder, stated to a group of tech CEOs, “Health is just so heavily regulated,” “it’s just a painful business to be in.”

The FDA was built for a world where most medical innovations came from large, multinational corporations that had the resources necessary to undergo expensive, extensive clinical trials. But it’s long past time for the FDA to adapt to a world where innovation can come from both large pharmaceutical companies and startups alike. New firms are a key source of competition and innovation, and the FDA needs to nurture those new firms instead of stifling them.

The FDA’s slow-moving bureaucracy has been obstructive for the rapid medical and drug innovation coming out of Silicon Valley. Take, for example, 23andMe, a revolutionary company which offered disease risk profiles based on genetic information. The FDA prevented 23andMe from offering information about disease risk profiles. Instead, 23andMe has focused on providing ancestral information. Recently the FDA approved two specific product offerings, but the era of personalized medicine is delayed.

Another example of how the FDA has failed to adapt to the startup era is their pre-submission program. The pre-submission program allows companies to get informal feedback on their ideas before conducting pre-clinical trials. However, even getting informal written feedback takes 75 to 90 days, a lifetime for an early stage startup. With more feedback from the FDA, more ideas would be brought before investors and more new drugs could be developed.

Last May, the Wall Street Journal reported that tech-savvy families were building their own automatic insulin pumps. The FDA was so slow in approving insulin pumps that 50 or more families simply built their own. Millions of sufferers of diabetes were subjected to unnecessary hardship because of an overly onerous regulatory process. Luckily, several months later the FDA did approve an automatic insulin pump.

The FDA is required to find that new drugs are both safe and effective before approving them. The 1962 Kefauver-Harris Amendments added the efficacy requirement for new drugs. Sam Peltzman, in the Journal of Political Economy, estimated the effect of the new requirements on the number of new drugs approved by the FDA. The figure below shows the rapid drop in the approval of new drugs, labeled here as new chemical entities (NCEs):nce

This is not because drugs that were otherwise ineffective were not being approved. A subsequent literature review in 1978, concluded: “The hypothesis that the observed decline in new product introductions has largely been concentrated in marginal or ineffective drugs is not generally supported by empirical analyses.” It’s possible that instead, fewer drugs were being developed in the first place.

O’Neill represents the best candidate to bring the FDA into the 21st century, into the age of startups, personalized medicine, and the rapid development of new drugs. He understands both the FDA as well as biotech startups. This gives him unique insight into how to reform the FDA, ensuring the FDA can be a partner, rather than a roadblock, for innovation. If the next 25 years can be as revolutionary for medicine as the past 25 years have been for computers, that would be tremendous, and O’Neill is determined to help us get there.

Follow Mark on Twitter.

PREMIUM ARTICLE: Subscribe To Keep Reading

Sign up

By subscribing you agree to our Terms of Use

You're signed up!

Sign up

By subscribing you agree to our Terms of Use

You're signed up!
Sign up

By subscribing you agree to our Terms of Use

You're signed up!

Sign up

By subscribing you agree to our Terms of Use

You're signed up!
Sign up

By subscribing you agree to our Terms of Use

You're signed up!

Sign Up

By subscribing you agree to our Terms of Use

You're signed up!
Sign up

By subscribing you agree to our Terms of Use

You're signed up!
Sign up

By subscribing you agree to our Terms of Use

You're signed up!
BENEFITS READERS PASS PATRIOTS FOUNDERS
Daily and Breaking Newsletters
Daily Caller Shows
Ad Free Experience
Exclusive Articles
Custom Newsletters
Editor Daily Rundown
Behind The Scenes Coverage
Award Winning Documentaries
Patriot War Room
Patriot Live Chat
Exclusive Events
Gold Membership Card
Tucker Mug

What does Founders Club include?

Tucker Mug and Membership Card
Founders

Readers,

Instead of sucking up to the political and corporate powers that dominate America, The Daily Caller is fighting for you — our readers. We humbly ask you to consider joining us in this fight.

Now that millions of readers are rejecting the increasingly biased and even corrupt corporate media and joining us daily, there are powerful forces lined up to stop us: the old guard of the news media hopes to marginalize us; the big corporate ad agencies want to deprive us of revenue and put us out of business; senators threaten to have our reporters arrested for asking simple questions; the big tech platforms want to limit our ability to communicate with you; and the political party establishments feel threatened by our independence.

We don't complain -- we can't stand complainers -- but we do call it how we see it. We have a fight on our hands, and it's intense. We need your help to smash through the big tech, big media and big government blockade.

We're the insurgent outsiders for a reason: our deep-dive investigations hold the powerful to account. Our original videos undermine their narratives on a daily basis. Even our insistence on having fun infuriates them -- because we won’t bend the knee to political correctness.

One reason we stand apart is because we are not afraid to say we love America. We love her with every fiber of our being, and we think she's worth saving from today’s craziness.

Help us save her.

A second reason we stand out is the sheer number of honest responsible reporters we have helped train. We have trained so many solid reporters that they now hold prominent positions at publications across the political spectrum. Hear a rare reasonable voice at a place like CNN? There’s a good chance they were trained at Daily Caller. Same goes for the numerous Daily Caller alumni dominating the news coverage at outlets such as Fox News, Newsmax, Daily Wire and many others.

Simply put, America needs solid reporters fighting to tell the truth or we will never have honest elections or a fair system. We are working tirelessly to make that happen and we are making a difference.

Since 2010, The Daily Caller has grown immensely. We're in the halls of Congress. We're in the Oval Office. And we're in up to 20 million homes every single month. That's 20 million Americans like you who are impossible to ignore.

We can overcome the forces lined up against all of us. This is an important mission but we can’t do it unless you — the everyday Americans forgotten by the establishment — have our back.

Please consider becoming a Daily Caller Patriot today, and help us keep doing work that holds politicians, corporations and other leaders accountable. Help us thumb our noses at political correctness. Help us train a new generation of news reporters who will actually tell the truth. And help us remind Americans everywhere that there are millions of us who remain clear-eyed about our country's greatness.

In return for membership, Daily Caller Patriots will be able to read The Daily Caller without any of the ads that we have long used to support our mission. We know the ads drive you crazy. They drive us crazy too. But we need revenue to keep the fight going. If you join us, we will cut out the ads for you and put every Lincoln-headed cent we earn into amplifying our voice, training even more solid reporters, and giving you the ad-free experience and lightning fast website you deserve.

Patriots will also be eligible for Patriots Only content, newsletters, chats and live events with our reporters and editors. It's simple: welcome us into your lives, and we'll welcome you into ours.

We can save America together.

Become a Daily Caller Patriot today.

Signature

Neil Patel